MIAMI, Dec. 29, 2025 — Leads & Copy — Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company, will participate in the StartUp Health Apollo House during JPM Healthcare Week in January 2026.
Longeveron focuses on developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions.
StartUp Health Alzheimer’s & Brain Moonshot, a mission-aligned community focused on accelerating breakthroughs in Alzheimer’s disease, Parkinson’s disease and related conditions, supports the Apollo House Founders & Funders Networking Summit. Health Moonshot Champions, including the Alzheimer’s Drug Discovery Foundation (ADDF) and Gates Ventures also support the summit. The summit will bring together founders, funders and industry leaders addressing Health Moonshots worldwide.
Longeveron will also host meetings with institutional investors and potential partners during JPM Healthcare Week. Those interested can contact info@longeveron.com to schedule a meeting with members of Longeveron’s senior management.
The Company’s lead investigational product is laromestrocel (LOMECEL-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program – Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program – Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
Source: Longeveron Inc.
